Tenaya Therapeutics, Inc.
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $225.0K
- Net income
- -$90.6M
- Total assets
- $146.9M
- Market cap
- $158.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $93.3M
- Operating income
- -$93.3M
- Income tax
- $0
- Net income
- -$90.6M
- EPS (basic)
- $-0.59
- EPS (diluted)
- $-0.59
Balance sheet
- Total assets
- $146.9M
- Current assets
- $105.6M
- Total liabilities
- $23.7M
- Current liabilities
- $15.4M
- Shareholders’ equity
- $123.3M
Cash flow
- Operating cash flow
- -$68.3M
- Investing cash flow
- $56.1M
- Financing cash flow
- $108.4M
- Net cash flow
- $96.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $158.0M
- EPS (diluted)
- $-0.59
- Shares outstanding
- 229.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $90.6M in FY2026.
- Trading 67% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tenaya Therapeutics, Inc..
Write a review
News about Tenaya Therapeutics, Inc.
News & sentiment via Polygon.io
